Cell Care Therapeutics is developing a new class of biologics that are derived from the secreted proteins and exosomes of mesenchymal stromal cells (MSCs).  The company’s novel secretome platform harnesses the signaling molecules of MSCs to promote the health of blood vessels and their surrounding tissue. The company is developing its first product for the treatment of diabetic macular edema, the leading cause of vision loss in working age adults.

It is increasingly recognized that the predominant therapeutic qualities of mesenchymal stromal stem cells come from the secretome, rather than from the cells themselves. Cell Care has developed a product engine to engineer and manufacture secretome based biologics that harness the therapeutic properties of mesenchymal stromal cells.

Diabetic retinopathy is the leading cause of vision loss in working age adults; approximately 120M globally suffer from this complication of diabetes.  Cell Care’s initial clinical target for CCT-101 is diabetic macular edema, a severe complication of diabetic retinopathy that degrades the central vision of approximately 24 million patients worldwide and 1,700,000 in the United States. Chronic diabetes mellitus may cause retinal microvascular and neuronal complications that result in severe vision loss if not properly treated.